CA2539551A1 - Adrenergic receptor snp for improved milking characteristics - Google Patents
Adrenergic receptor snp for improved milking characteristics Download PDFInfo
- Publication number
- CA2539551A1 CA2539551A1 CA002539551A CA2539551A CA2539551A1 CA 2539551 A1 CA2539551 A1 CA 2539551A1 CA 002539551 A CA002539551 A CA 002539551A CA 2539551 A CA2539551 A CA 2539551A CA 2539551 A1 CA2539551 A1 CA 2539551A1
- Authority
- CA
- Canada
- Prior art keywords
- dna
- milking
- allele
- beta2
- pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108060003345 Adrenergic Receptor Proteins 0.000 title description 4
- 102000017910 Adrenergic receptor Human genes 0.000 title description 4
- 108700028369 Alleles Proteins 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 244000309464 bull Species 0.000 claims abstract description 17
- 239000002773 nucleotide Substances 0.000 claims abstract description 15
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 14
- 108091008146 restriction endonucleases Proteins 0.000 claims abstract description 11
- 101000959443 Bos taurus Beta-2 adrenergic receptor Proteins 0.000 claims abstract description 8
- 238000012216 screening Methods 0.000 claims abstract description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 claims abstract description 3
- 108020004414 DNA Proteins 0.000 claims description 30
- 241000283690 Bos taurus Species 0.000 claims description 29
- 241001465754 Metazoa Species 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000523 sample Substances 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 102220082846 rs373113507 Human genes 0.000 claims description 9
- 108091093088 Amplicon Proteins 0.000 claims description 8
- 230000001488 breeding effect Effects 0.000 claims description 7
- 238000009395 breeding Methods 0.000 claims description 6
- 230000002596 correlated effect Effects 0.000 claims description 4
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 229930024421 Adenine Natural products 0.000 abstract description 3
- 229960000643 adenine Drugs 0.000 abstract description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 3
- 235000013365 dairy product Nutrition 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 208000004396 mastitis Diseases 0.000 description 8
- 239000013615 primer Substances 0.000 description 8
- 210000001082 somatic cell Anatomy 0.000 description 8
- 238000003556 assay Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 101710152983 Beta-2 adrenergic receptor Proteins 0.000 description 5
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 5
- 244000144980 herd Species 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 3
- 108010053770 Deoxyribonucleases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 101100378538 Bos taurus ADRB2 gene Proteins 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 101150033809 ADRB2 gene Proteins 0.000 description 1
- 101100490566 Arabidopsis thaliana ADR2 gene Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101100269260 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH2 gene Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 102000000072 beta-Arrestins Human genes 0.000 description 1
- 108010080367 beta-Arrestins Proteins 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Disclosed herein is a method for screening for the allele associated with a desired SCS phenotype, which comprises: obtaining a DNA sample from a bull to be tested for the desired SCS phenotype; and detecting the presence of an adenine at position 11 in a gene encoding a bovine beta2-adrenoreceptor. Also disclosed is a milking attribute PCR-RFLP kit containing a pair of primers which flank the 11th nucleotide position of the bovine beta2-adrenoreceptor gene, and a restriction enzyme specific for the CCCGGG site, which can be SmaI.
Description
ADRENERGIC RECEPTOR SNP FOR IMPROVED MILKING CHARACTERISTICS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
[0002) Not applicable.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003) The present invention relates, in general, to the field of molecular biology, human and bovine genetics, and desirable milking characteristics. In particular this invention provides a method for using genetics to predict the milking characteristics of cows.
[0004) Various publications or patent are referred to throughout this application to describe the state of the art to which the invention pertains. Each of this publications or patents is incorporated by reference herein. Complete citations of scientific publications are set forth in the text or at the end of the specification.
[0005] Domestic animals are bred for improvement to the useful attributes of the animals. For cows, one very useful attribute is their milking characteristics, both volume of milk and rate of milking. Many dairy cows are artificially inseminated using semen from sires purchased from companies engaged in selling quality improvement genetics for milking cows.
However, while the overall statistical average of the milking characteristics of the daughters of a particular sire can be measured, it is yet not possible to predict with any degree of success the milking characteristics of a particular progeny created by breeding a cow with a particular bull.
Better understanding of the genetics of milking traits will be needed in order to more accurately predict the milking characteristics of a particular daughter.
However, while the overall statistical average of the milking characteristics of the daughters of a particular sire can be measured, it is yet not possible to predict with any degree of success the milking characteristics of a particular progeny created by breeding a cow with a particular bull.
Better understanding of the genetics of milking traits will be needed in order to more accurately predict the milking characteristics of a particular daughter.
[0006] It is known that some milking characteristics are linked to other traits. A
relationships between adrenoceptor concentrations and milkability in primiparous' cows have been elucidated by Roets, et al.("Relationship between milkability and adrenoceptor concentrations in teat tissue in primiparous cows", J Dairy Sci 69(12):2131-3131, 1986). Later, Roets et al. ("Relationship between numbers of alpha2- and beta2-adrenoceptors in teat tissue and blood cells and milkability of primiparous cows", J Dairy Sci 72(12):3304-33-13, 199) reported on the numbers of alpha2- and beta2-adrenoceptors in teat tissue and blood cells and milkability in primiparous cows. Subsequently, Roets et al.("Relationship between numbers of alpha2- and beta2-adrenoceptors on blood cells of bulls and milkability of their daughters", J
Dairy Sci, 62 567-575, 1995) analyzed the numbers of alpha2- and beta2-adrenoceptors on the blood cells of bulls and the milkability of their daughters. In addition, Blum et al.("Catecholamines, oxytocen and milk removal in dairy cows", J Dairy Res, 56(2):167-177, 1989) reported that treatment with phentolamine (an alpha-adrenergic blocker) and isoproterenol (a beta-adrenoceptor agonist) each facilitated milk removal. Brown et al.
("Relationship of milking rate to somatic cell count", J Dairy Sci, 69(3):850-854, 1986) raised the possibility that milking speed was correlated with both somatic cell score (SCS) and mastitis.
Many studies have established correlations between mastitis and SCS (see, for example, MacMillan et al., "Associations between dry cow therapy, clinical mastitis, and somatic cell count score with milk and fat production in ten New Zealand dairy herds", J Dairy Sci, 66(2):259-265, 1983; Reneau, "Effective use of dairy herd improvement somatic cell counts in mastitis control", J Dairy Sci, 69(6):1708-1720, 1986; and McClelland, "A comparison of objective and subject measures of milking speed on Canadian Holstein-Friesians", University of Guelph, 1983).
Further, a positive correlation between milking speed and SCS was confirmed by Boettcher et al.
("Development of an udder health index for sire selection based on somatic cell score, udder conformation, and milking speed", J Dairy Sci, 81(4):1157-1168, 1998).
relationships between adrenoceptor concentrations and milkability in primiparous' cows have been elucidated by Roets, et al.("Relationship between milkability and adrenoceptor concentrations in teat tissue in primiparous cows", J Dairy Sci 69(12):2131-3131, 1986). Later, Roets et al. ("Relationship between numbers of alpha2- and beta2-adrenoceptors in teat tissue and blood cells and milkability of primiparous cows", J Dairy Sci 72(12):3304-33-13, 199) reported on the numbers of alpha2- and beta2-adrenoceptors in teat tissue and blood cells and milkability in primiparous cows. Subsequently, Roets et al.("Relationship between numbers of alpha2- and beta2-adrenoceptors on blood cells of bulls and milkability of their daughters", J
Dairy Sci, 62 567-575, 1995) analyzed the numbers of alpha2- and beta2-adrenoceptors on the blood cells of bulls and the milkability of their daughters. In addition, Blum et al.("Catecholamines, oxytocen and milk removal in dairy cows", J Dairy Res, 56(2):167-177, 1989) reported that treatment with phentolamine (an alpha-adrenergic blocker) and isoproterenol (a beta-adrenoceptor agonist) each facilitated milk removal. Brown et al.
("Relationship of milking rate to somatic cell count", J Dairy Sci, 69(3):850-854, 1986) raised the possibility that milking speed was correlated with both somatic cell score (SCS) and mastitis.
Many studies have established correlations between mastitis and SCS (see, for example, MacMillan et al., "Associations between dry cow therapy, clinical mastitis, and somatic cell count score with milk and fat production in ten New Zealand dairy herds", J Dairy Sci, 66(2):259-265, 1983; Reneau, "Effective use of dairy herd improvement somatic cell counts in mastitis control", J Dairy Sci, 69(6):1708-1720, 1986; and McClelland, "A comparison of objective and subject measures of milking speed on Canadian Holstein-Friesians", University of Guelph, 1983).
Further, a positive correlation between milking speed and SCS was confirmed by Boettcher et al.
("Development of an udder health index for sire selection based on somatic cell score, udder conformation, and milking speed", J Dairy Sci, 81(4):1157-1168, 1998).
[0007] The DNA sequence in and around the bovine beta2-adrenergic receptor (ADRB2) gene was in public genome databases (accession numbers 286037; Einspanier et al., "Expression of the beta2 adrenergic receptor in the cattle", direct submission to Genbank, accession No. 286037, 1997 and AF331034; Schimpf et al., "Genetic mapping of the ADRB2 gene on cattle chromosome 7", Anim. Genet. 32(6):390, 2001). These sequences included the ADRBZ coding region (1257 bases inclusive from the ATG start to the TAA stop codon), as well as the 223 bases upstream from the ATG start codon and the 550 bases downstream from the TAA stop codon.
[0008] What is needed is a way of determining which bulls will produce cows with improved milkability and a method of improving the results of a breeding program for milkability.
BRIEF SUMMARY OF THE INVENTION
BRIEF SUMMARY OF THE INVENTION
[0009] Disclosed herein is a method for breeding cows for improved milking characteristics including the step of screening the genotype of the parents of the cow for the allele associated with a desired SCS phenotype. The method has the steps of obtaining a DNA
sample from a bull to be tested for the desired SCS phenotype; and detecting the presence of an adenine at position 11 in a gene encoding a bovine beta2-adrenoreceptor. The method can be performed by direct sequencing, primer extension, restriction length fragment polymorphism, and allele-specific hybridization.
sample from a bull to be tested for the desired SCS phenotype; and detecting the presence of an adenine at position 11 in a gene encoding a bovine beta2-adrenoreceptor. The method can be performed by direct sequencing, primer extension, restriction length fragment polymorphism, and allele-specific hybridization.
(00010] In another embodiment, a method of identifies a bull whose daughter cows have a short milking duration This method has the steps of obtaining a sample of DNA
from a bull;
combining the DNA with a pair of PCR probes comprising SEQ IDs l and 2 or SEQ
IDS 3 and 4; incubating the DNA under conditions permitting the DNA bounded by the PCR
probes to produce DNA amplicons; isolating the DNA amplicons; combining the DNA
amplicons with a restriction enzyme specific for CCCGGG for a sufficient time to produce a mixture of DNA
fragments from the amplicons comprising CCCGGG; applying the DNA fragment mixture to a gel and permitting migration of the mixture components for a time sufficient for them to separate; and observing the sizes of DNA on the gel, with the largest fragments being correlated with the A genotype and with better SCS phenotype, and the smaller fragments being associated with the C genotype and less desirable SCS phenotype.
from a bull;
combining the DNA with a pair of PCR probes comprising SEQ IDs l and 2 or SEQ
IDS 3 and 4; incubating the DNA under conditions permitting the DNA bounded by the PCR
probes to produce DNA amplicons; isolating the DNA amplicons; combining the DNA
amplicons with a restriction enzyme specific for CCCGGG for a sufficient time to produce a mixture of DNA
fragments from the amplicons comprising CCCGGG; applying the DNA fragment mixture to a gel and permitting migration of the mixture components for a time sufficient for them to separate; and observing the sizes of DNA on the gel, with the largest fragments being correlated with the A genotype and with better SCS phenotype, and the smaller fragments being associated with the C genotype and less desirable SCS phenotype.
[00011] In another embodiment a milking attribute PCR-RFLP kit contains a pair of primers which flank the 11th nucleotide position of the bovine beta2-adrenoreceptor gene, and a restriction enzyme specific for the CCCGGG site. The restriction enzyme can be SmaI. The primer pairs are selected from pair 1 (SEQ ID Nos 1 and 2) or from pair 2 (SEQ
ll~ Nos 3 and 4).
ll~ Nos 3 and 4).
[00012] Other objects, features and advantage of the present invention will become apparent to one of skill in the art after review of the specification and claims.
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[00013] Not applicable.
DETAILED DESCRIPTION OF THE INVENTION
DETAILED DESCRIPTION OF THE INVENTION
[00014] It is disclosed here that genetic differences in the allele for the beta2-adrenoceptor (ADR2) gene are associated with the milking characteristics of milking cows.
This makes possible the use of genetic tools and analysis in breeding of cows to start to predict with accuracy the milking characteristics of daughters of specific bulls bred to specific maternal COWS.
This makes possible the use of genetic tools and analysis in breeding of cows to start to predict with accuracy the milking characteristics of daughters of specific bulls bred to specific maternal COWS.
[00015] We began the work described here by proposing that DNA sequence polymorphisms in and around bovine beta2-adrenoceptor (ADR$2) may cause or be associated with genes that cause the observed associations. First, we subcloned and sequenced bovine ADRB2, extending the region of known sequence beyond what was previously publicly available. Sequence obtained through this work, not previously in the public domain, includes 875 additional bases upstream from that described above. These bases are a total of 1099 that are 5' to the ATG start codon. An additional 695 bases downstream from the previously reported bases also were sequenced. These bases include a total of 1245 bases 3' to the TAA
stop codon.
stop codon.
[00016] With this information in hand, we were then able to design oligonucleotide primers to be used to amplify and perform locus-specific re-sequencing of genomic DNA
spanning regions of the bovine ADRB2 gene. These primers were used to amplify genomic DNA from 24 Holstein and 12 Brown Swiss dairy cows. After comparative genomic sequence was obtained, we analyzed the sequence using polyPhred software (Washington University, St.
Louis, MO) and identified, among others, a Single Nucleotide Polymorphism (SNP) sequence at position 11, inclusive of the start ATG (hereafter referred to as "A11C"). The published sequence indicates the presence of a cytosine (C) nucleotide. We discovered a variant allele with an adenine (A) nucleotide at that position. Substitution of A for C at the nucleotide position 11 altered the amino acid sequence of ADRB2 protein by replacing a proline with a histidine at amino acid position 4 of the protein.
spanning regions of the bovine ADRB2 gene. These primers were used to amplify genomic DNA from 24 Holstein and 12 Brown Swiss dairy cows. After comparative genomic sequence was obtained, we analyzed the sequence using polyPhred software (Washington University, St.
Louis, MO) and identified, among others, a Single Nucleotide Polymorphism (SNP) sequence at position 11, inclusive of the start ATG (hereafter referred to as "A11C"). The published sequence indicates the presence of a cytosine (C) nucleotide. We discovered a variant allele with an adenine (A) nucleotide at that position. Substitution of A for C at the nucleotide position 11 altered the amino acid sequence of ADRB2 protein by replacing a proline with a histidine at amino acid position 4 of the protein.
[00017] Subsequently we designed and validated a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay able to detect the presence of A
and/or C
nucleotides) at the A11 C locus. This assay is based on the presence or absence of the srnal restriction enzyme recognition site (CCCGGG) in DNA fragments which have been amplified by one of two primer pairs. The A allele at the Al l C locus changes this sequence to CACGGG, which is not recognized, therefore is not digested by sma~ and consequently is identified as a heavier nucleotide in the PCR-RFLP test.
and/or C
nucleotides) at the A11 C locus. This assay is based on the presence or absence of the srnal restriction enzyme recognition site (CCCGGG) in DNA fragments which have been amplified by one of two primer pairs. The A allele at the Al l C locus changes this sequence to CACGGG, which is not recognized, therefore is not digested by sma~ and consequently is identified as a heavier nucleotide in the PCR-RFLP test.
[00018] This polymorphism was found to be associated with milking characteristics. In particular, the A allele at the A11C locus is associated with higher somatic cell score (SMS) and therefore with a faster milking speed. This makes is possible to breed dairy cattle to increase the proportion of the herds having the A allele at the Al l C locus, to improve the overall milking speed of the herd. The A allele is effective in both the heterozygous and homozygous conditions to improve the performance of the animal.
[00019) "Polymorphism" refers generally to the ability of an organism or gene to occur in two or more different forms. In particular for purposes of the present invention, "polymorphism" refers to two or more different forms of the same gene.
[00020) "Single Nucleotide Polymorphism" or "SNP" refers to a polymorphism that results from a difference in a single nucleotide.
[00021) A "Restriction Enzyme" refers to an endonuclease which bins to double stranded DNA at a specific nucleotide sequence and then, if both strands of the DNA
lack the appropriate modification at that sequence (including but not limited to methylation), cleaves the DNA either at the recognition sequence or at another site in the DNA molecule.
Restriction enzymes are denoted by three-letter abbreviations followed by a strain designation and/or a Roman numeral distinguishing different enzymes from the same species or strain. Recognition sequences are written S' to 3' for one strand only. Examples of restriction enzymes include SmaI, BamHi, BcII, EcoRI, HindIII, and XbaI.
lack the appropriate modification at that sequence (including but not limited to methylation), cleaves the DNA either at the recognition sequence or at another site in the DNA molecule.
Restriction enzymes are denoted by three-letter abbreviations followed by a strain designation and/or a Roman numeral distinguishing different enzymes from the same species or strain. Recognition sequences are written S' to 3' for one strand only. Examples of restriction enzymes include SmaI, BamHi, BcII, EcoRI, HindIII, and XbaI.
[00022) The term "Allele" refers generally to any of one or more alternative forms of a given gene or DNA segment; both or all alleles of a given gene are concerned with the same trait or characteristic, but the product or function coded for by a particular allele differs qualitatively and/or quantitatively from that coded for by other alleles of that gene. In a diploid cell or organism the members of an allelic pair (i.e., the two alleles of a given gene} occupy corresponding positions (loci) on a pair of homologous chromosomes; if these alleles are genetically identical the cell or organism is said to be homozygous. If the alleles are genetically different, the cell or organism is said to be heterozygous with respect to the particular gene.
[00023) The polynucleotides of the present invention may be prepared by two general methods: (1) They may be synthesized from appropriate nucleotide triphosphates, or (2) they may be isolated from biological sources. Both methods utilize protocols well known in the art.
The availability of nucleotide sequence information enables preparation of an isolated nucleic acid molecule of the invention by oligonucleotide synthesis. Synthetic oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 37A
DNA
Synthesizer or similar devices. The resultant construct may be purified according to methods known in the art, such as high performance liquid chromatography (I~LC).
Complementary segments thus produced may be annealed such that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire long double-stranded molecule. A synthetic DNA molecule so constructed may then be cloned and amplified in an appropriate vector.
The availability of nucleotide sequence information enables preparation of an isolated nucleic acid molecule of the invention by oligonucleotide synthesis. Synthetic oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 37A
DNA
Synthesizer or similar devices. The resultant construct may be purified according to methods known in the art, such as high performance liquid chromatography (I~LC).
Complementary segments thus produced may be annealed such that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire long double-stranded molecule. A synthetic DNA molecule so constructed may then be cloned and amplified in an appropriate vector.
[00024] The invention will be better understood upon consideration of the following non-limiting Examples. Unless otherwise specified, general cloning procedures, such as those set forth in Sambrook et al., MOLECULAR CLONING, Cold Spring Harbor Laboratory (1989) or Ausubel et al. CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons (2001), are used.
Example 1. Assessment of mRNA levels in leukocytes of cows with fast vs. slow-millcing rates.
Example 1. Assessment of mRNA levels in leukocytes of cows with fast vs. slow-millcing rates.
[00025] Eight animals were selected by the duration of their milking and grouped as either slow or fast. For initial determinations, slow-milking animals were numbered 90, 264, 279 and 321. Fast-milking animals were numbered 272, 273, 281 and 289. Their blood (about 15 mL) was collected in EDTA-filled Vacutainers (BD, Franklin Lakes, NJ).
Known sequences from NCBI along with the program "Oligo" were used to design primer sets specific for GAPDH, alpha2-, beta 1-, beta2-adrenoreceptors, and beta-arrestin.
Known sequences from NCBI along with the program "Oligo" were used to design primer sets specific for GAPDH, alpha2-, beta 1-, beta2-adrenoreceptors, and beta-arrestin.
[00026] From the blood samples, RNA was isolated using the RNeasy RNA
isolation protocol (Qiagen, Valencia, CA). One volume of whole blood was mixed with 5 volumes of erythrocyte lysis buffer. The mixture was incubated on ice, and during the incubation mixed by vortexing briefly twice. The mixture was next centrifuged at 400 g for 10 min at 4°C. The supernatant was discarded and the leukocyte pellet saved. The leukocyte pellet was added to more Buffer EL and vortexed to resuspend the leukocytes. The mixture was again centrifuged, after which the supernatant was discarded. The leukocyte pellet was loosened by flicking the tube. Buffer RLT (Qiagen)(with 10 ~.l ~i-mercaptoethanol added per 1 ml buffer) was added to the leukocytes; for a starting blood volume of 4.0 ml or less, 2.0 ml was added; and for a greater blood volume, 4.0 ml was added. Next the mixture was homogenized until the sample was homogeneous. An equal volume of 70% alcohol was added to the homogenized lysate and vigorously shaken. Finally, the sample, including any precipitate that may have formed, was applied to an RNeasy midi spin column placed in a 15-ml centrifuge tube and centrifuged for 3000 to 5000 g for 5 min. For samples in excess of 4.0 ml, the extra sample was applied successively to the same column and the flow-through discarded. After the flow-through had been discarded, 4.0 ml of Buffer RW 1 was added to the RNeasy column and centrifuged at 3000-5000 for 5 min to wash the column. The flow-through was discarded. Next 2.5 ml of Buffer RPE (diluted with 4 volumes of ethanol (96-100%) was added to the column which was again centrifuged at 3000-5000 for 2 min. Another 2.5 ml Buffer RPE was added to the column which was centrifuged at 3000-5000 for 5 min to dry the spin-column membrane.
RNA was eluted from the column adding 150 p.l or 250 ~1 RNase-free water to the column, which was left to stand for 1 min and then centrifuged at 3000-5000 g for 3 min. A second volume of RNase-free water was added to the column and spun down. The RNA was then salt-precipitated according to the manufacturer's protocol.
isolation protocol (Qiagen, Valencia, CA). One volume of whole blood was mixed with 5 volumes of erythrocyte lysis buffer. The mixture was incubated on ice, and during the incubation mixed by vortexing briefly twice. The mixture was next centrifuged at 400 g for 10 min at 4°C. The supernatant was discarded and the leukocyte pellet saved. The leukocyte pellet was added to more Buffer EL and vortexed to resuspend the leukocytes. The mixture was again centrifuged, after which the supernatant was discarded. The leukocyte pellet was loosened by flicking the tube. Buffer RLT (Qiagen)(with 10 ~.l ~i-mercaptoethanol added per 1 ml buffer) was added to the leukocytes; for a starting blood volume of 4.0 ml or less, 2.0 ml was added; and for a greater blood volume, 4.0 ml was added. Next the mixture was homogenized until the sample was homogeneous. An equal volume of 70% alcohol was added to the homogenized lysate and vigorously shaken. Finally, the sample, including any precipitate that may have formed, was applied to an RNeasy midi spin column placed in a 15-ml centrifuge tube and centrifuged for 3000 to 5000 g for 5 min. For samples in excess of 4.0 ml, the extra sample was applied successively to the same column and the flow-through discarded. After the flow-through had been discarded, 4.0 ml of Buffer RW 1 was added to the RNeasy column and centrifuged at 3000-5000 for 5 min to wash the column. The flow-through was discarded. Next 2.5 ml of Buffer RPE (diluted with 4 volumes of ethanol (96-100%) was added to the column which was again centrifuged at 3000-5000 for 2 min. Another 2.5 ml Buffer RPE was added to the column which was centrifuged at 3000-5000 for 5 min to dry the spin-column membrane.
RNA was eluted from the column adding 150 p.l or 250 ~1 RNase-free water to the column, which was left to stand for 1 min and then centrifuged at 3000-5000 g for 3 min. A second volume of RNase-free water was added to the column and spun down. The RNA was then salt-precipitated according to the manufacturer's protocol.
[00027] Next RNA was treated with DNA-free DNase to remove trace levels of DNA, according to the manufacturer's protocol (Ambion, Austin, TX). To the RNA
sample purified as described above, were added 0.1 volume of 1 OX DNase I Buffer and 1 ~.1 of DNase I (2 units) to the RNA, which solution was mixed gently and incubated at 37°C for 20-30 min. Ambion DNase Inactivation reagent was resuspended by flicking or vortexing. From that tube, the greater of 0.1 volume or 5 ~l was added to the sample and mixed well. The tube was incubated for 2 min at room temperature. The tube was next centrifuged at 10,000 g for about 1 min to pellet the DNase inactivation reagent.
sample purified as described above, were added 0.1 volume of 1 OX DNase I Buffer and 1 ~.1 of DNase I (2 units) to the RNA, which solution was mixed gently and incubated at 37°C for 20-30 min. Ambion DNase Inactivation reagent was resuspended by flicking or vortexing. From that tube, the greater of 0.1 volume or 5 ~l was added to the sample and mixed well. The tube was incubated for 2 min at room temperature. The tube was next centrifuged at 10,000 g for about 1 min to pellet the DNase inactivation reagent.
[00028] Spectrophotometry was then used to determine RNA concentration, and 1 pg RNA was loaded on a 1% agarose gel using ethidium bromide to ensure quality.
[00029] Following the manufacturer's protocol, cDNA templates were made from the RNA using Omniscript (Qiagen) for Real Time PCR analysis. The Omniscript l OX
Buffer RT, dNTP mix and RNase-free water were first thawed and mixed by vortexing. Qiagen RNase inhibitor was diluted to a final concentration of 10 units/~,l in lx Buffer RT
and mixed by vortexing briefly. Master mix (2.0 pl of l Ox Buffer RT, 2.0 pl dNTP mix, 2.0 ~l oligo dT
primer (10 uM), 0.5 ~.l Rnase inhibitor (10 unitsl~l), 1.0 ~l Omniscript reverse transcriptase and double distilled water) was prepared on ice. Master solution was distributed to the various tubes, and template RNA (0.6 to 0.68 ~.I/tube) was added and mixed. The resulting solutions were incubated at 37°C for 60 min.
Buffer RT, dNTP mix and RNase-free water were first thawed and mixed by vortexing. Qiagen RNase inhibitor was diluted to a final concentration of 10 units/~,l in lx Buffer RT
and mixed by vortexing briefly. Master mix (2.0 pl of l Ox Buffer RT, 2.0 pl dNTP mix, 2.0 ~l oligo dT
primer (10 uM), 0.5 ~.l Rnase inhibitor (10 unitsl~l), 1.0 ~l Omniscript reverse transcriptase and double distilled water) was prepared on ice. Master solution was distributed to the various tubes, and template RNA (0.6 to 0.68 ~.I/tube) was added and mixed. The resulting solutions were incubated at 37°C for 60 min.
[00030] All samples were run by LightCycler (Idaho Technology, Inc., Salt Lake City, UT) protocol using the SYBR-green kit from Roche Molecular Biochemicals, except for beta2-adrenoreceptor, for which the SYBR-green kit (Qiagen) was used. Samples were run in duplicate, and all were normalized using GAPDH. Cycle thresholds (determined by the second derivative growth curve) of samples were then compared between the groups of slow and fast milkers. To determine if there were any significant differences between slow and fast milkers, the SAS statistical package was used to perform a Pearson correlation coefficient. The results _7_ suggested that duration of milking and rate of milk removal are associated with the amount of beta2-adrenoreceptor mRNA levels in blood, and it was decided to more thoroughly characterize the beta2-adrenoreceptor gene in cattle.
[00031] It was discovered that there was a polymorphism of the beta2-adrenoreceptor at the 1 lth nucleotide (A replaced C in some instances, resulting in a substitution of histidine for proline at the fourth amino acid).
Example 2. Associations Between A11C Genotype and SCS and/or Milking Speed in Dairy Cows [00032] Bovine DNAs are available from the Cooperative Dairy DNA Repository (CDDR) population (Gene Evaluation and Mapping Laboratory, Bldg. 200 Rm 2A, ARS-USDA, BARC-East Beltsville, MD 20705). SCS phenotypes have been obtained for all CDDR
animals. For a subset of the CDDR animals, there also are data on the milking speed (MS).
First, CDDR animals with MS data were genotyped, along with a subset of the remainder of the CDDR animals representing "high" and "low" Somatic Cell Score (SCS) phenotypic classes, with the A11C assay. DNA samples were obtained and assayed. Data sets were distributed and analyzed in duplicate. The analysis revealed a correlation between A11C and SCS.
j00033] Six hundred sixty three animals from the CDDR were genotyped for the Al l C
locus using the either of the following pairs of primers:
TGGAACTGGCTGAACTGACA (SEQ ID NO 1}
AGTTGATGGCTTCCTTGTGG (SEQ ID NO 2) AGGTCCGCTCGC'.CGAGG (SEQ ID NO 3 GTTCCAGCGTGACGTTTTG (SEQ ID NO 4) [00034] Table 1 shows a disproportionate distribution of Al l C genotypes into "High" and "Low" SCS phenotypic categories.
Table 1. A11C Genotypes and SCS distribution of 663 CDDR bulls.
AA AC CC Total High # 9 88 248 345 Low # 5 55 258 318 Total 14 143 506 663 Prop. High 0.643 0.615 0.490 0.520 Prop. Low 0.357 0.385 0.510 0.480 _g_ [00035] In addition, Table 2 contains average estimated transmitting abilities (ETA) for SCS and frequencies by Al 1C genotype. Results from statistical analyses of the data indicate that genotypes AA, AC and CC are significantly different from the mean SCS
(p<0.025) and that genotypes AA and AC are significantly higher than the mean SCS (p<0.01).
Furthermore, animals with the CC genotype have significantly different (i.e., lower) SCS
phenotypes than animals with AA and AC genotypes (p<0.05).
Table 2. Average SCS ETA and frequency by Al l C genotype among 663 CDDR
bulls.
AA AC CC Total SCS ETA 314.5 312.8 307.0 0.520 Genotype Freq. 0.021 0.216 0.763 [00036] Table 3 shows the distribution of milking speed (MS) classifications according to genotype, and Table 4 illustrates the average ETA for MS by genotype. Because of the small number ofAA animals, there is not a significant association between MS and A11C genotype at the 5% level. However, the trend in Table 3 clearly shows that the CC genotype has a lower proportion of bulls transmitting fast MS.
Table 3. Al 1C Genotypes and Milking Speed distribution of 663 CDDR bulls.
AA AC CC Total Fast # 13 46 108 167 Slow # 7 36 120 163 Total 20 82 228 330 Prop. Fast 0.650 0.561 0.474 0.506 Prop. Slow 0.350 0.439 0.526 0.494 [00037] In Table 4, the AA genotype tends to have a higher average ETA for MS.
Table 4. Average ETA for milking speed and frequency by A11C genotype among bulls.
AA AC CC
MS ETA 70 68.81707 64.02609 Genotype Freq. 0.061 0.248 0.691 (00038] From these tables it appears that the AA and AC genotypes (that are significantly associated SCS) axe also associated with higher milking speed. This is in agreement with studies (McClelland, "A comparison of objective and subject measures of milking speed on Canadian Holstein-Friesians", University of Guelph, 1983, and Boettcher et al., "Development of an udder health index for sire selection based on somatic cell score, udder conformation, and milking speed", J Dairy Sci 81(4):1157-1168, 1998) that have shown that higher milking speed is genetically correlated with higher SCS and mastitis incidence. Since the bulls that had MS
ETAs represented only a subset (330) of the total group (663), it is likely that with a larger sample size, significant association could be shown between MS and the Al 1 C
locus.
[00039] This discovery enables for the first time the testing and selection of animals for breeding andlor alternative management practices based on the results of the inventive assay.
The assay results correlate with the SCS and enable the choice of animals with improved MS
and mastitis resistance. In addition to using these discoveries to select animals for phenotypes related to SCS, these discoveries can also be used to select animals in an attempt to effect population changes in MS and mastitis resistance. Applying the assay will enable the selection of animals with SCS which will ultimately improve the herd averages for MS and mastitis resistance.
[00040] This invention also includes a kit containing reagents that can be used to identify allelic composition at the loci described herein.
[00041] The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modif cation within the scope of the appended claims.
Example 2. Associations Between A11C Genotype and SCS and/or Milking Speed in Dairy Cows [00032] Bovine DNAs are available from the Cooperative Dairy DNA Repository (CDDR) population (Gene Evaluation and Mapping Laboratory, Bldg. 200 Rm 2A, ARS-USDA, BARC-East Beltsville, MD 20705). SCS phenotypes have been obtained for all CDDR
animals. For a subset of the CDDR animals, there also are data on the milking speed (MS).
First, CDDR animals with MS data were genotyped, along with a subset of the remainder of the CDDR animals representing "high" and "low" Somatic Cell Score (SCS) phenotypic classes, with the A11C assay. DNA samples were obtained and assayed. Data sets were distributed and analyzed in duplicate. The analysis revealed a correlation between A11C and SCS.
j00033] Six hundred sixty three animals from the CDDR were genotyped for the Al l C
locus using the either of the following pairs of primers:
TGGAACTGGCTGAACTGACA (SEQ ID NO 1}
AGTTGATGGCTTCCTTGTGG (SEQ ID NO 2) AGGTCCGCTCGC'.CGAGG (SEQ ID NO 3 GTTCCAGCGTGACGTTTTG (SEQ ID NO 4) [00034] Table 1 shows a disproportionate distribution of Al l C genotypes into "High" and "Low" SCS phenotypic categories.
Table 1. A11C Genotypes and SCS distribution of 663 CDDR bulls.
AA AC CC Total High # 9 88 248 345 Low # 5 55 258 318 Total 14 143 506 663 Prop. High 0.643 0.615 0.490 0.520 Prop. Low 0.357 0.385 0.510 0.480 _g_ [00035] In addition, Table 2 contains average estimated transmitting abilities (ETA) for SCS and frequencies by Al 1C genotype. Results from statistical analyses of the data indicate that genotypes AA, AC and CC are significantly different from the mean SCS
(p<0.025) and that genotypes AA and AC are significantly higher than the mean SCS (p<0.01).
Furthermore, animals with the CC genotype have significantly different (i.e., lower) SCS
phenotypes than animals with AA and AC genotypes (p<0.05).
Table 2. Average SCS ETA and frequency by Al l C genotype among 663 CDDR
bulls.
AA AC CC Total SCS ETA 314.5 312.8 307.0 0.520 Genotype Freq. 0.021 0.216 0.763 [00036] Table 3 shows the distribution of milking speed (MS) classifications according to genotype, and Table 4 illustrates the average ETA for MS by genotype. Because of the small number ofAA animals, there is not a significant association between MS and A11C genotype at the 5% level. However, the trend in Table 3 clearly shows that the CC genotype has a lower proportion of bulls transmitting fast MS.
Table 3. Al 1C Genotypes and Milking Speed distribution of 663 CDDR bulls.
AA AC CC Total Fast # 13 46 108 167 Slow # 7 36 120 163 Total 20 82 228 330 Prop. Fast 0.650 0.561 0.474 0.506 Prop. Slow 0.350 0.439 0.526 0.494 [00037] In Table 4, the AA genotype tends to have a higher average ETA for MS.
Table 4. Average ETA for milking speed and frequency by A11C genotype among bulls.
AA AC CC
MS ETA 70 68.81707 64.02609 Genotype Freq. 0.061 0.248 0.691 (00038] From these tables it appears that the AA and AC genotypes (that are significantly associated SCS) axe also associated with higher milking speed. This is in agreement with studies (McClelland, "A comparison of objective and subject measures of milking speed on Canadian Holstein-Friesians", University of Guelph, 1983, and Boettcher et al., "Development of an udder health index for sire selection based on somatic cell score, udder conformation, and milking speed", J Dairy Sci 81(4):1157-1168, 1998) that have shown that higher milking speed is genetically correlated with higher SCS and mastitis incidence. Since the bulls that had MS
ETAs represented only a subset (330) of the total group (663), it is likely that with a larger sample size, significant association could be shown between MS and the Al 1 C
locus.
[00039] This discovery enables for the first time the testing and selection of animals for breeding andlor alternative management practices based on the results of the inventive assay.
The assay results correlate with the SCS and enable the choice of animals with improved MS
and mastitis resistance. In addition to using these discoveries to select animals for phenotypes related to SCS, these discoveries can also be used to select animals in an attempt to effect population changes in MS and mastitis resistance. Applying the assay will enable the selection of animals with SCS which will ultimately improve the herd averages for MS and mastitis resistance.
[00040] This invention also includes a kit containing reagents that can be used to identify allelic composition at the loci described herein.
[00041] The present invention is not limited to the embodiments described and exemplified above, but is capable of variation and modif cation within the scope of the appended claims.
Claims (7)
1. A method for breeding cows for desired milking characteristics comprising the steps of:
a. identifying the allele of the bovine beta2-adrenergic receptor gene in at least one potential parent animals; and b. breeding male and female animals to create a daughter having at least one allele of the beta2-adregenic receptor gene associated with improved milking characteristics.
a. identifying the allele of the bovine beta2-adrenergic receptor gene in at least one potential parent animals; and b. breeding male and female animals to create a daughter having at least one allele of the beta2-adregenic receptor gene associated with improved milking characteristics.
2. The method of claim 1 wherein the method for identifying the allele includes isolating DNA from the parent and screening with a method selected from the group consisting of direct sequencing, primer extension, restriction length fragment polymorphism, and allele-specific hybridization.
3. The method of claim 1 whereby the screening method is intended to identify A11C alleles.
4. A method of identifying a bull whose daughter cows will have a faster milking time, the method comprising the steps of a. obtaining a sample of DNA from a bull;
b. combining the DNA with a pair of PCR probes comprising SEQ IDs 1 and 2 or SEQ IDS 3 and 4;
c. incubating the DNA under conditions permitting the DNA bounded by the PCR
probes to produce DNA amplicons;
d. isolating the DNA amplicons;
e. combining the DNA amplicons with a restriction enzyme specific for CCCGGG
for a sufficient time to produce a mixture of DNA fragments from the amplicons comprising CCCGGG;
f. applying the DNA fragment mixture to a gel and permitting migration of the mixture components for a time sufficient for them to separate; and g. observing the sizes of DNA on the gel, with the largest fragments being correlated with the A genotype and with better SCS phenotype, and the smaller fragments being associated with the C genotype and less desirable SCS phenotype.
b. combining the DNA with a pair of PCR probes comprising SEQ IDs 1 and 2 or SEQ IDS 3 and 4;
c. incubating the DNA under conditions permitting the DNA bounded by the PCR
probes to produce DNA amplicons;
d. isolating the DNA amplicons;
e. combining the DNA amplicons with a restriction enzyme specific for CCCGGG
for a sufficient time to produce a mixture of DNA fragments from the amplicons comprising CCCGGG;
f. applying the DNA fragment mixture to a gel and permitting migration of the mixture components for a time sufficient for them to separate; and g. observing the sizes of DNA on the gel, with the largest fragments being correlated with the A genotype and with better SCS phenotype, and the smaller fragments being associated with the C genotype and less desirable SCS phenotype.
5. A milking attribute PCR-RFLP kit, which comprises:
a pair of primers which flank the 11th nucleotide position of the bovine beta2-adrenoreceptor gene, and a restriction enzyme specific for the CCCGGG site.
a pair of primers which flank the 11th nucleotide position of the bovine beta2-adrenoreceptor gene, and a restriction enzyme specific for the CCCGGG site.
6. The kit of claim 5 wherein the restriction enzyme is SmaI.
7. The kit of claim 5 wherein the primer pairs are selected from pair 1 (SEQ
ID Nos 1 and 2) or from pair 2 (SEQ ID Nos 3 and 4).
ID Nos 1 and 2) or from pair 2 (SEQ ID Nos 3 and 4).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50511303P | 2003-09-23 | 2003-09-23 | |
US60/505,113 | 2003-09-23 | ||
PCT/US2004/030774 WO2005030789A1 (en) | 2003-09-23 | 2004-09-21 | Adrenergic receptor snp for improved milking characteristics |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2539551A1 true CA2539551A1 (en) | 2005-04-07 |
Family
ID=34392977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002539551A Abandoned CA2539551A1 (en) | 2003-09-23 | 2004-09-21 | Adrenergic receptor snp for improved milking characteristics |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1673382A4 (en) |
CN (1) | CN100422202C (en) |
AU (1) | AU2004276248A1 (en) |
BR (1) | BRPI0414583A (en) |
CA (1) | CA2539551A1 (en) |
RU (1) | RU2006113558A (en) |
WO (1) | WO2005030789A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008140467A2 (en) * | 2006-09-29 | 2008-11-20 | Pfizer Inc. | Genetic markers and methods for improving dairy productivity and fitness traits |
CN101693923B (en) * | 2009-11-09 | 2012-02-22 | 山东奥克斯生物技术有限公司 | HSP70A1A gene SNP loci, application and kit for selecting heat-resistant cows |
CN110106250B (en) * | 2019-05-28 | 2020-11-27 | 中国农业大学 | Molecular marker related to resistance of metabolic diseases of dairy cows in perinatal period and application of molecular marker |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5041371A (en) * | 1989-03-15 | 1991-08-20 | Wisconsin Alumni Research Foundation | Genetic marker for superior milk products in dairy cattle |
US6498009B1 (en) * | 1997-10-10 | 2002-12-24 | University Of Cincinnati | β-adrenergic receptor polymorphisms |
US6593092B2 (en) * | 2000-04-04 | 2003-07-15 | Abbott Laboratories | Beta 2 adrenergic polymorphism detection |
-
2004
- 2004-09-21 AU AU2004276248A patent/AU2004276248A1/en not_active Abandoned
- 2004-09-21 BR BRPI0414583-6A patent/BRPI0414583A/en not_active IP Right Cessation
- 2004-09-21 EP EP04784592A patent/EP1673382A4/en not_active Withdrawn
- 2004-09-21 CN CNB2004800271385A patent/CN100422202C/en not_active Expired - Fee Related
- 2004-09-21 RU RU2006113558/13A patent/RU2006113558A/en not_active Application Discontinuation
- 2004-09-21 WO PCT/US2004/030774 patent/WO2005030789A1/en active Application Filing
- 2004-09-21 CA CA002539551A patent/CA2539551A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN100422202C (en) | 2008-10-01 |
EP1673382A1 (en) | 2006-06-28 |
WO2005030789A1 (en) | 2005-04-07 |
CN1852916A (en) | 2006-10-25 |
EP1673382A4 (en) | 2006-10-18 |
AU2004276248A1 (en) | 2005-04-07 |
BRPI0414583A (en) | 2006-11-07 |
RU2006113558A (en) | 2007-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005078133B1 (en) | Marker assisted best linear unbiased predicted (ma-blup): software adaptions for practical applications for large breeding populations in farm animal species | |
US20070186298A1 (en) | Follistatin gene as a genetic marker for reproductive and performance traits in pigs | |
MXPA06009452A (en) | Leptin promoter polymorphisms and uses thereof. | |
AU2009275988B2 (en) | A genetic marker test for Brachyspina and fertility in cattle | |
JP2015526099A (en) | Genetic markers for mastitis resistance | |
Mišeikienė et al. | The influence of TLR4 gene polymorphisms on milk quality and composition of Lithuanian Holstein cows | |
MX2007008623A (en) | Dna markers for cattle growth. | |
MX2007008621A (en) | Dna markers for increased milk production in cattle. | |
WO2011028134A9 (en) | Biological markers and uses therefor | |
US20060275793A1 (en) | Association between markers in the leptin gene and carcass traits in commercial feedlot steer and heifers | |
KR101796158B1 (en) | SNP markers of NAT9 gene for prediction of pigs litter size and methods for selection of fecund pigs using the same | |
Wu et al. | Restriction fragment length polymorphism in the exon 2 of the BoLA-DRB3 gene in Chinese Holstein of the south China | |
US8003328B2 (en) | Bovine polymorphisms and methods of predicting bovine traits | |
US20100009374A1 (en) | Sire early selection for male fertility using single nucleotide polymorphisms (snps) of the dazl gene | |
CA2539551A1 (en) | Adrenergic receptor snp for improved milking characteristics | |
US20070209084A1 (en) | Adrenergic Receptor SNP for Improved Milking Characteristics | |
KR101289484B1 (en) | Method of genetic test for diagnosis of marbling trait in Korean cattle | |
US20080118914A1 (en) | Follistatin gene as a genetic marker for first parity litter size in pigs | |
MX2009001506A (en) | Leptin and growth hormone receptor gene markers associated with rearing, carcass traits and productive life in cattle. | |
Mišeikienė et al. | Utjecaj polimorfizma gena TLR4 na kvalitetu i sastav mlijeka krava holstein pasmine u Litvi | |
MXPA06003211A (en) | Adrenergic receptor snp for improved milking characteristics | |
KR101796160B1 (en) | SNP markers of DACT3 gene for prediction of pigs litter size and methods for selection of fecund pigs using the same | |
EP2149611A1 (en) | A genetic marker test for brachyspina and fertility in cattle | |
VĂTĂŞESCU-BALCAN et al. | A METHOD FOR DIAGNOSIS OF DEFICIENCY OF URIDINE MONOPHOSPHATE SYNTHASE IN CATTLE | |
Todd | Investigation of leptin genotypes and economically important dairy traits in jersey cows. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |